Dr Reddy's Labs launches Ziprasidone Mesylate for Injection in US Market

Hyderabad and Princeton: Dr Reddy's Laboratories Ltd. has announced the launch of Ziprasidone Mesylate for Injection, 20 mg (base)/mL Single-dose Vials, the therapeutic generic equivalent of Geodon® (ziprasidone mesylate) Injection, 20 mg/mL, approved by the U.S. Food and Drug Administration (USFDA).

"We're pleased to bring the first generic of Ziprasidone Mesylate for Injection to market for patients who will benefit from access to affordable medicine. With every new product launch, we believe we are making healthcare more affordable by delivering value to the pharmacy," explains Marc Kikuchi, Chief Executive Officer, North America Generics, Dr Reddy's Laboratories. "This is a great addition to our injectable offering in the U.S. market as we continue to augment our portfolio and drive growth within the hospital segment."

The Geodon® brand had U.S. sales of approximately $21.8 million MAT for the most recent twelve months ending in January 2020 according to IQVIA Health.

Read also: Dr Reddy's Laboratories launches generic of Naproxen, Esomeprazole Magnesium Delayed-Release Tablets

Dr Reddy's Laboratories Ltd. is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products – Dr Reddy's offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations.

Its major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr Reddy's operates in markets across the globe. Its major markets include – USA, India, Russia & CIS countries, and Europe.

Read also: Dr Satish Reddy appointed as CII Southern region chairman